Compare VSTM & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSTM | VOR |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2011 | 2021 |
| Metric | VSTM | VOR |
|---|---|---|
| Price | $7.19 | $18.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | $17.22 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 3.0M | 646.7K |
| Earning Date | 11-05-2026 | 10-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.49 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,914,000.00 | N/A |
| Revenue This Year | $248.46 | N/A |
| Revenue Next Year | $34.25 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 209.14 | N/A |
| 52 Week Low | $3.43 | $6.50 |
| 52 Week High | $10.82 | $26.00 |
| Indicator | VSTM | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 31.85 | 40.76 |
| Support Level | $5.26 | $17.62 |
| Resistance Level | $8.59 | $18.28 |
| Average True Range (ATR) | 0.57 | 1.20 |
| MACD | -0.31 | -0.14 |
| Stochastic Oscillator | 0.48 | 9.97 |
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.